Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
ASCO-GU 2026 – late-breakers in focus
Welireg, Padcev, and a surprise fillip for Flare.
Astra’s Claudin reckoning approaches
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
AstraZeneca goes early with Gracell
AZD0120’s first pivotal trial will test settings as early as the second line.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Astra ditches a Duo
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
